|Molecular profiling for breast cancer: a comprehensive review|
M Kittaneh, AJ Montero, S Glück
Biomarkers in cancer 5, BIC. S9455, 2013
|A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.|
JA Sosman, M Kittaneh, MPJK Lolkema, MA Postow, G Schwartz, ...
Journal of Clinical Oncology 32 (15_suppl), 9009-9009, 2014
|Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.|
EL Kwak, P LoRusso, O Hamid, F Janku, M Kittaneh, DVT Catenacci, ...
Journal of Clinical Oncology 33 (3_suppl), 1-1, 2015
|Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.|
PLR Jeffrey R. Infante, John D. Powderly, Howard A, SCR Institute, ...
J Clin Oncol, abstr 3044, 2013
|Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid TumorsAMG 337 in Patients with Advanced Solid Tumors|
DS Hong, P LoRusso, O Hamid, F Janku, M Kittaneh, DVT Catenacci, ...
Clinical Cancer Research 25 (8), 2403-2413, 2019
|Phase 1/2 study of oral rucaparib: Final phase 1 results.|
RS Kristeleit, HA Burris, P LoRusso, MR Patel, US Asghar, F El-Khouly, ...
Journal of Clinical Oncology, 2014
|First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.|
DS Hong, P LoRusso, O Hamid, DM Beaupre, F Janku, R Khan, ...
Journal of Clinical Oncology 32 (15_suppl), 2508-2508, 2014
|Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.|
M Kittaneh, C Berkelhammer
J Transl Med. 2018 Jul 13;16(1):194. doi: 10.1186/s12967-018-1559-7., 2018
|Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.|
A Bardia, S Modi, M Chavez-Mac Gregor, M Kittaneh, AJ Marino, ...
Journal of Clinical Oncology 32 (15_suppl), 535-535, 2014
|Current Cancer Treatment-Novel Beyond Conventional Approaches|
|Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.|
A Jimeno, P LoRusso, RM Strother, JR Diamond, L Plato, A Younger, ...
Journal of Clinical Oncology 31 (15_suppl), 2502-2502, 2013
|BAP1: role in carcinogenesis and clinical implications|
DA Kobrinski, H Yang, M Kittaneh
Translational Lung Cancer Research 9 (Suppl 1), S60, 2020
|Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable …|
J Abraham, R Coleman, A Elias, FA Holmes, K Kalinsky, M Kittaneh, ...
Breast Cancer Research and Treatment 171 (1), 11-20, 2018
|Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer|
S Palacio, A Loaiza-Bonilla, M Kittaneh, C Kyriakopoulos, RE Ochoa, ...
Anticancer research 34 (1), 301-306, 2014
|Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.|
A Patnaik, P LoRusso, HA Ball, E Bahceci, G Yuen, KP Papadopoulos, ...
Journal of Clinical Oncology 31 (15_suppl), 2602-2602, 2013
|Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women|
M Kittaneh, S Glück
Breast Cancer, 2011
|Phase Ib/II study of LEE011 (CDK4/6 inhibitor) and LGX818 (BRAF inhibitor) in BRAF-mutant melanoma|
M Taylor, J Sosman, R Gonzalez, MS Carlino, M Kittaneh, MP Lolkema, ...
Annals of Oncology 25, iv374, 2014
|Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study|
TL Werner, J Sachdev, EM Swisher, M Gutierrez, M Kittaneh, MN Stein, ...
Cancer medicine 7 (6), 2360-2369, 2018
|A roundtable discussion of the Breast Cancer Therapy Expert Group (BCTEG): clinical developments and practice guidance on human epidermal growth factor receptor 2 (HER2 …|
R Mahtani, FA Holmes, S Badve, H Caldera, R Coleman, E Mamounas, ...
Clinical Breast Cancer 20 (3), e251-e260, 2020
|Breast Cancer Therapy Expert Group (BCTEG): A Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early Stage Breast Cancer|
CV Muaiad Kittaneh, Sunil Badve, Humberto Caldera, Robert Coleman, Matthew P ...
Clinical Breast Cancer, 2020